Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23312494 | 0.79 | PDK2 (0.44) | PDK2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL22112407 | 0.76 | MAP2 (0.43) | PDK2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL28344391 | 0.75 | PTPRC (0.40) | PTGS1PTGS2IDO1TDO2 | |
| SCHEMBL29282856 | 0.73 | S100A4 (0.46) | PDK2HSD11B1IDO1S100A4 | |
| SCHEMBL25340105 | 0.70 | NPC1 (0.35) | NPC1HPGDRAB9ASMN1; SMN2GRM2 | |
| SCHEMBL29290421 | 0.69 | PTPRC (0.46) | PDK2NPC1HPGDSMN1; SMN2S100A4 | |
| SCHEMBL8974306 | 0.69 | DHODH (0.44) | NPC1HPGDSMN1; SMN2GRM2PTGS1 | |
| SCHEMBL263907 | 0.68 | PDK2 (0.37) | PDK2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL29363756 | 0.68 | PDK2 (0.37) | PDK2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL29280128 | 0.68 | PTPRC (0.43) | PTGS1PTGS2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018022-B2 | Heterocyclic compound, organic light emitting diode comprising same, composition for organic layer of organic light emitting diode, and method for manufacturing organic light emitting diode | LT MATERIALS CO., LTD. (KR) | 2024-06-25 | — | — | US | disclosed |
| US-12018022-B2 | Heterocyclic compound, organic light emitting diode comprising same, composition for organic layer of organic light emitting diode, and method for manufacturing organic light emitting diode | LT MATERIALS CO., LTD. (KR) | 2024-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018022-B2 | Heterocyclic compound, organic light emitting diode comprising same, composition for organic layer of organic light emitting diode, and method for manufacturing organic light emitting diode | ODC1, AOX1, CYP1B1 | PDK2 1501/4885NPC1 1924/4885HPGD 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.